TTK Healthcare Limited

As of June 30, 2026, TTK Healthcare Limited carries a market capitalization of 12.87B, placing it among publicly traded companies globally. Its enterprise value stands at 12.87B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, TTK Healthcare Limited has 14.13M shares outstanding.

As of June 30, 2026, TTK Healthcare Limited trades at a trailing price-to-earnings ratio of 19.34.

As of June 30, 2026, TTK Healthcare Limited trades at an EV/EBITDA multiple of 40.86 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.41 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 56.43 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 12.87B versus a market cap of 12.87B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 3.55M in revenue per employee across its workforce of 2,566.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, TTK Healthcare Limited recorded 235.51M in income tax expense. That works out to an effective tax rate of 26.13, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 901.24M, leaving 665.73M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, TTK Healthcare Limited's stock has declined approximately 20.02% over the past 52 weeks. The 50-day moving average sits at 1,069.91, while the 200-day moving average is 964.51.

Over the twelve months ended June 30, 2026, TTK Healthcare Limited generated 9.11B in revenue and converted that into 665.73M in net income, yielding earnings per share of 47.11. EBITDA reached 315.02M, while operating income came in at 268.89M.

Over the twelve months ended June 30, 2026, TTK Healthcare Limited posted a gross margin of 53.93, reflecting its pricing power and cost economics. The operating margin of 2.95 and net profit margin of 7.31 provide insight into operational efficiency.